Mr. Enright is a managing director and founder of Longitude Capital. Prior to Longitude Capital, Mr. Enright was a managing director of Pequot Ventures where he co-led the life sciences investment practice. Prior to Pequot, he was a managing member of the Delta Opportunity Fund at Diaz & Altschul Capital Management. Mr. Enright began his investment career at PaineWebber Development Corporation. Mr. Enright also has significant life sciences operations experience, including senior executive positions at Valentis, Boehringer Mannheim (acquired by Roche) and Sandoz (now known as Novartis). Mr. Enright currently serves on the boards of Aimmune, Aptinyx, Jazz Pharmaceuticals, Orbus Therapeutics and SutroVax. Selected prior board memberships include Codexis, Corcept Therapeutics, Esperion Therapeutics, Horizon Pharmaceuticals, InfaCare Pharmaceutical, MAP Pharmaceuticals, Prestwick Pharmaceuticals (acquired by Lundbeck), and Sequenom.
Mr. Enright holds a BS in biological sciences from Stanford University, and an MBA from the Wharton School of Business at the University of Pennsylvania.